Expert Interview
A second look at standard of care and the potential use of remibrutinib as part of treatment for CSU in light of the positive top-line results from the Phase III REMIX-1 and REMIX-2 studies
Ticker(s): NVS- Head of the Allergy Asthma and Immunology Service at the Emek MedicalCenter, Afula, and Clinical Associate Professor at the Rappaport Faculty of Medicine,Technion-Israel Institute of Technology, Haifa, Israel
- Treats 200 patients with urticaria
- An author and co-author of over 100 peer reviewed medicalscientific publications
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
